Perlecan Domain V Induces VEGf Secretion in Brain Endothelial Cells through Integrin α5β1 and ERK-Dependent Signaling Pathways
Figure 3
DV increases VEGF-A at mRNA and protein level through an ERK-dependent pathway.
(A) qPCR analysis of VEGF-A mRNA in BECs +/− DV and +/−10 µM LY294002 or 10 µM AktIV. GAPDH was used as internal control. N = 3, ***P<0.001 in comparison between DV-treated and untreated cells, ##P<0.01 in comparison between inhibitors and untreated groups. (B) Similar analysis as in (A) demonstrating that 10 µM U0126 (MEK inhibitor) treatment significantly blunted DV-induced VEGF-A mRNA up-regulation. N = 3. ***P<0.001 in comparison between DV-treated and untreated cells. (C) Secreted VEGF ELISA profile from BECs following treatment with DV, LY294002, or AktIV alone or in combination Note the significant up-regulation of secreted VEGF following DV, LY294002 or AktIV treatment. N = 3, ***P<0.001 in comparison between DV-treated and untreated cells, ##P<0.01 in comparison between LY and AktIV treated groups versus untreated group. (D) U0126 treatment significantly inhibited VEGF secretion from BECs following DV treatment. N = 3. ***P<0.001 in comparison between DV-treated and untreated cells.